Clay Thorp - 19 May 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc

Role
Director
Signature
/s/ John P. Sharp, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
19 May 2022
Net transactions value
$0
Form type
4
Filing time
20 May 2022, 16:46:12 UTC
Previous filing
17 May 2022
Next filing
24 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Non-employee Director Stock Option (right to buy) Award $0 +17,500 $0.000000 17,500 19 May 2022 Common Stock 17,500 $0.8419 Direct F1
transaction PHASQ Restricted Stock Units Award $0 +3,750 $0.000000 3,750 19 May 2022 Common Stock 3,750 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F3 The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.